Recent Updates
Recently added Catalysts
IVVD Positive Sentiment Score: 70/100

Invivyd to Participate at the Jefferies Global Healthcare Conference

Key Takeaway: Invivyd, Inc. will participate in the Jefferies Global Healthcare Conference on June 6, 2024, where its management team will engage in a fireside chat and hold investor meetings. The conference presents an opportunity for potential investors to connect directly with the company's leadership. Invivyd recently received emergency use authorization from the U.S. FDA for its first monoclonal antibody targeting serious viral diseases, showcasing its innovative approach in the biopharmaceutical sector.

Conference Participation Details

Jefferies Global Healthcare Conference
Date: November 18, 2025
Time: 11:30 a.m. GMT / 6:30 a.m. ET
Location: London
Format: Fireside Chat

How to Access

Investors and the general public can listen to both sessions live at:

https://investor.viatris.com

Archived versions will be available following the live events for a limited time.

Market Sentiment Analysis

POSITIVE FACTORS

  • Participation at the prestigious Jefferies Global Healthcare Conference
  • Opportunity for direct investor engagement and communication
  • Recent emergency use authorization for their monoclonal antibody indicates successful innovation

Full Press Release Details

WALTHAM, Mass., June 03, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced that its management team is scheduled to participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024 at 3:00 p.m. ET in New York, NY.
In addition to the fireside chat, the management team will host investor meetings at the conference. Investors participating in the conference who are interested in meeting with Invivyd management should contact their Jefferies representative.
A live webcast of the fireside chat will be available in the investor section of the company's website at investors.invivyd.com and will be archived for approximately 30 days following the presentation.
Invivyd, Inc. (Nasdaq: IVVD) is a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, beginning with SARS-CoV-2. The company’s proprietary INVYMAB™ platform approach combines state-of-the-art viral surveillance and predictive modeling with advanced antibody engineering. INVYMAB is designed to facilitate the rapid, serial generation of new monoclonal antibodies (mAbs) to address evolving viral threats. In March 2024, Invivyd received emergency use authorization (EUA) from the U.S. FDA for its first mAb in a planned series of innovative antibody candidates. Visit https://invivyd.com/ to learn more.

Frequently Asked Questions

When is Invivyd's fireside chat at the Jefferies Conference?

Invivyd's fireside chat is scheduled for June 6, 2024, at 3:00 p.m. ET.

How can investors meet Invivyd management at the conference?

Investors interested in meeting Invivyd management should contact their Jefferies representative.

Where can I watch the Invivyd fireside chat?

The fireside chat will be available on Invivyd's investor website and archived for 30 days.

What is Invivyd's focus as a biopharmaceutical company?

Invivyd focuses on protecting against serious viral infectious diseases, starting with SARS-CoV-2.

What technology does Invivyd use for antibody development?

Invivyd employs the INVYMAB™ platform for rapid generation of monoclonal antibodies.

Last updated: Jun 3, 2024